Home / Business and Economy / Pharma Giant's Sales Soar on Cancer Drugs
Pharma Giant's Sales Soar on Cancer Drugs
15 Jul
Summary
- Innovative Medicine unit sales rose 7.8% to $16.38 billion.
- Cancer drugs Darzalex and Carvykti fueled significant growth.
- Tremfya, a psoriasis and IBD drug, saw sales surge 72.5%.
The pharmaceutical sector's Innovative Medicine unit achieved a notable 7.8% year-over-year sales increase, generating $16.38 billion during the last quarter. This impressive financial performance was substantially driven by the success of several key therapeutic products.
Among the top performers were cancer treatments Darzalex and Carvykti, which significantly boosted revenue. Furthermore, immunology drugs, including Tremfya, and neuroscience products like Spravato and Caplyta, played a crucial role in this growth. Tremfya, specifically targeting psoriasis and inflammatory bowel disease, saw an exceptional 72.5% surge in sales, reaching $2 billion for the quarter. Darzalex, a critical medication for blood cancer, contributed an additional $4.2 billion in sales.
